In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

For Devices, an Elusive Consumer Appeal

Executive Summary

While pharmaceutical companies have begun to explore the blow-out potential of a direct to consumer appeal in quality of life issues, medical device firms have sat on the sidelines. They've targeted seriously ill patients on the outer fringes of conditions like obesity and erectile dysfunction, but as of yet, haven't really gone after the huge central market.

You may also be interested in...



Direct-to-Consumer Advertising

Drug company spending on direct-to-consumer advertising is soaring and could reach $10 billion, or as much as 30% of all promotional spending, by 2005, if current trends continue. But some powerful groups, most notably, doctors, pharmacists and managed care organizations, have begun to express their concern, worried that such advertising inappropriately influences patient prescribing.

Direct to Consumer Advertising Confronts Managed Care

DTC advertising of prescription drugs is becoming more accepted by physicians, patients, and manufacturers but still represents only a small proportion of the money pharmaceutical companies spend on promotion. Some argue that DTC could be a natural fit with disease management programs but neither advertisers nor managed care have figured out a way to make it work for both because of naturally conflicting goals.

Speedy Approval Of Gilead’s Veklury Sets Stage For Pediatric Expansion, Dosing Refinement

US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.

Topics

Related Companies

UsernamePublicRestriction

Register

OM011995

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel